Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 4, 2009, Pages 471-477

  Yamasaki, Kazumi ^a   Kurimura, Mayumi ^b   Kasai, Takatoshi ^c   Sagara, Mina ^d   Kodama, Tatsuhiko ^e   Inoue, Kenji ^f  

^a Narao Hospital   (Japan)

^b Kamigoto Hospital   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d Perseus Proteomics   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Biomarker; Healthy population; Metabolic syndrome; Pentraxin 3

Indexed keywords

PENTRAXIN 3; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; SEX CHARACTERISTICS; TRIGLYCERIDES;

EID: 63849234720     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.110     Document Type: Article

References (16)

1. Grundy SM, Bazzarre T, Cleeman J, D'Agostino RB Sr, Hill M, Houston-Miller N, et al. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: writing group I. Circulation 2000;101:E3-11.
2. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
3. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
4. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994;84:3483-93.
5. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003;33:2886-93.
6. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41.
7. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7.
8. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stentinduced inflammation and neointimal thickening. Atherosclerosis 2008;197:368-74.
9. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81.
10. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007;2: 889-97.
11. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008;3:976-85.
12. Koji Y, Tomiyama H, Yamada J, Yambe M, Motobe K, Shiina K, et al. Relationship between arterial stiffness and the risk of coronary artery disease in subjects with and without metabolic syndrome. Hypertens Res 2007; 30:243-7.
13. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-8.
14. Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055-64.
15. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Presta M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Throm Vasc Biol 2005;25:1837-42.
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.